Skip to main content
Erschienen in: Familial Cancer 4/2010

01.12.2010

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study

verfasst von: Noralane M. Lindor, Kiley J. Johnson, Hayden Harvey, V. Shane Pankratz, Susan M. Domchek, Katherine Hunt, Marcia Wilson, M. Cathie Smith, Fergus Couch

Erschienen in: Familial Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

A number of models have been developed to predict the probability that a person carries a detectable germline mutation in the BRCA1 or BRCA2 genes. Their relative performance in a clinical setting is variable. To compare the performance characteristics of a web-based BRCA1/BRCA2 gene mutation prediction model: the PENNII model (www.​afcri.​upenn.​edu/​itacc/​penn2), with studies done previously at our institution using four other models including LAMBDA, BRCAPRO, modified PENNI (Couch) tables, and Myriad II tables collated by Myriad Genetics Laboratories. Proband and family cancer history data were analyzed from 285 probands from unique families (27 Ashkenazi Jewish; 277 female) seen for genetic risk assessment in a multispecialty tertiary care group practice. All probands had clinical testing for BR.CA1 and BRCA2 mutations conducted in the same single commercial laboratory. The performance for PENNII results were assessed by the area under the receiver operating characteristic curve (AUC) of sensitivity versus 1-specificity, as a measure of ranking. The AUCs of the PENNII model were higher for predicting BRCA1 than for BRCA2 (81 versus 72%). The overall AUC was 78.7%. PENN II model for BRCA1/2 prediction performed well in this population with higher AUC compared with our experience using four other models. The ease of use of the PENNII model is compatible with busy clinical practices.
Literatur
1.
Zurück zum Zitat Antoniou AC, Durocher F, Smith P et al (2005) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8(1):R3CrossRefPubMed Antoniou AC, Durocher F, Smith P et al (2005) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8(1):R3CrossRefPubMed
2.
Zurück zum Zitat Evans DG, Shenton A, Woodward E et al (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155CrossRefPubMed Evans DG, Shenton A, Woodward E et al (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155CrossRefPubMed
3.
Zurück zum Zitat Milne RL, Osorio A, Cajal TR et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14(9):2861–2869CrossRefPubMed Milne RL, Osorio A, Cajal TR et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14(9):2861–2869CrossRefPubMed
4.
Zurück zum Zitat Marroni F, Aretini P, D’Andrea E et al (2004) Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 12(11):899–906CrossRefPubMed Marroni F, Aretini P, D’Andrea E et al (2004) Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 12(11):899–906CrossRefPubMed
5.
Zurück zum Zitat Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329–1333CrossRefPubMed Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329–1333CrossRefPubMed
6.
Zurück zum Zitat Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15CrossRefPubMed Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15CrossRefPubMed
7.
Zurück zum Zitat Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23(8):1656–1663CrossRefPubMed Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23(8):1656–1663CrossRefPubMed
8.
Zurück zum Zitat Sogaard M, Kjaer SK, Gayther S (2006) Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 85(1):93–105CrossRefPubMed Sogaard M, Kjaer SK, Gayther S (2006) Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 85(1):93–105CrossRefPubMed
9.
Zurück zum Zitat National Comprehensive Cancer Network (2008) NCCN clinical practice guidelines in oncology. Colorectal cancer screening. Available via www.nccn.org. Cited 15 Dec 2009 National Comprehensive Cancer Network (2008) NCCN clinical practice guidelines in oncology. Colorectal cancer screening. Available via www.​nccn.​org. Cited 15 Dec 2009
10.
Zurück zum Zitat Lindor NM, McMaster ML, Lindor CJ et al (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38:1–93PubMed Lindor NM, McMaster ML, Lindor CJ et al (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38:1–93PubMed
11.
Zurück zum Zitat Lindor NM, Lindor RA, Apicella C et al (2007) Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. Fam Cancer 6(4):473–482CrossRefPubMed Lindor NM, Lindor RA, Apicella C et al (2007) Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. Fam Cancer 6(4):473–482CrossRefPubMed
12.
Zurück zum Zitat Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
14.
Zurück zum Zitat Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425–431CrossRefPubMed Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425–431CrossRefPubMed
15.
Zurück zum Zitat Wacholder S, Hartge P, Prentice R et al (2010) Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362(11):986–993CrossRefPubMed Wacholder S, Hartge P, Prentice R et al (2010) Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362(11):986–993CrossRefPubMed
16.
Zurück zum Zitat Apicella C, Andrews L, Hodgson SV et al (2003) Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 5(6):R206–R216CrossRefPubMed Apicella C, Andrews L, Hodgson SV et al (2003) Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 5(6):R206–R216CrossRefPubMed
17.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed
18.
Zurück zum Zitat Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158CrossRefPubMed Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158CrossRefPubMed
19.
Zurück zum Zitat Berry DA, Iversen ESJ, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712CrossRefPubMed Berry DA, Iversen ESJ, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712CrossRefPubMed
20.
Zurück zum Zitat Couch FJ, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415CrossRefPubMed Couch FJ, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415CrossRefPubMed
21.
Zurück zum Zitat National Cancer Institute (2003) Surveillance, epidemiology, and end results SEER program stat database: incidence–SEER 9 regs public-use. Version 5, 2nd edn. National Cancer Institute, Bethesda, MD National Cancer Institute (2003) Surveillance, epidemiology, and end results SEER program stat database: incidence–SEER 9 regs public-use. Version 5, 2nd edn. National Cancer Institute, Bethesda, MD
Metadaten
Titel
Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study
verfasst von
Noralane M. Lindor
Kiley J. Johnson
Hayden Harvey
V. Shane Pankratz
Susan M. Domchek
Katherine Hunt
Marcia Wilson
M. Cathie Smith
Fergus Couch
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9348-3

Weitere Artikel der Ausgabe 4/2010

Familial Cancer 4/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.